FIELD: biotechnology, in particular production of corticotropin-releasing factor 2 receptor (CRF2R) agonists.
SUBSTANCE: CRF2R agonist protein is produced as derivative of CRF, urocortine I, urocortine II urocortine III, sauvagine, urotensine I and other connate peptides by amino acid displacement in protein sequences. Obtained CRF2R agonist is useful in pharmaceutical composition for prophylaxis and treatment of disorders associated with CRF2R in host.
EFFECT: effective agent for prophylaxis and treatment of disorders modulated with CRF2R, such as muscle dystrophy.
25 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGONISTS OF CORTICOTROPIN-RELEASING FACTOR (CRFR) RECEPTOR AND THEIR USING | 2003 |
|
RU2294333C2 |
| AGONISTS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR | 2003 |
|
RU2286995C2 |
| METHODS FOR IDENTIFYING COMPOUNDS USED FOR REGULATION OF MUSCLE MASS OR FUNCTION WITH APPLYING RECEPTORS OF CORTICOTROPIN RELEASING-FACTOR | 2002 |
|
RU2260805C2 |
| UROCORTIN PROTEINS AND THEIR USING | 2001 |
|
RU2278871C2 |
| UROCORTIN-III, ITS ANALOG (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2305109C2 |
| COMPOSITIONS AND METHODS RELATED TO SOLUBLE G-PROTEIN CONJUGATE RECEPTORS (SGPCR) | 2006 |
|
RU2423378C2 |
| APPLICATION OF GROWTH HORMONE FRAGMENTS | 2012 |
|
RU2639474C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 2013 |
|
RU2655811C2 |
| IMPROVED ANTIBODIES GDF-8 ANTAGONISTS AND THEIR USE | 2013 |
|
RU2630634C2 |
